RU2728710C2 - Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) - Google Patents

Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) Download PDF

Info

Publication number
RU2728710C2
RU2728710C2 RU2018118177A RU2018118177A RU2728710C2 RU 2728710 C2 RU2728710 C2 RU 2728710C2 RU 2018118177 A RU2018118177 A RU 2018118177A RU 2018118177 A RU2018118177 A RU 2018118177A RU 2728710 C2 RU2728710 C2 RU 2728710C2
Authority
RU
Russia
Prior art keywords
seq
patient
antibody
secukinumab
antigen
Prior art date
Application number
RU2018118177A
Other languages
English (en)
Russian (ru)
Other versions
RU2018118177A3 (cg-RX-API-DMAC10.html
RU2018118177A (ru
Inventor
Кристиан МАНН
Брайан ПОРТЕР
Ханно РИЧАРДС
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2018118177A publication Critical patent/RU2018118177A/ru
Publication of RU2018118177A3 publication Critical patent/RU2018118177A3/ru
Application granted granted Critical
Publication of RU2728710C2 publication Critical patent/RU2728710C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018118177A 2015-10-19 2016-10-14 Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) RU2728710C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562243381P 2015-10-19 2015-10-19
US62/243,381 2015-10-19
PCT/IB2016/056166 WO2017068472A1 (en) 2015-10-19 2016-10-14 Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020124276A Division RU2020124276A (ru) 2015-10-19 2016-10-14 Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)

Publications (3)

Publication Number Publication Date
RU2018118177A RU2018118177A (ru) 2019-11-21
RU2018118177A3 RU2018118177A3 (cg-RX-API-DMAC10.html) 2020-02-17
RU2728710C2 true RU2728710C2 (ru) 2020-07-30

Family

ID=57223732

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018118177A RU2728710C2 (ru) 2015-10-19 2016-10-14 Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)
RU2020124276A RU2020124276A (ru) 2015-10-19 2016-10-14 Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020124276A RU2020124276A (ru) 2015-10-19 2016-10-14 Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)

Country Status (11)

Country Link
US (2) US20190330328A1 (cg-RX-API-DMAC10.html)
EP (1) EP3365011A1 (cg-RX-API-DMAC10.html)
JP (4) JP6858766B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180064415A (cg-RX-API-DMAC10.html)
CN (1) CN108367074A (cg-RX-API-DMAC10.html)
AU (4) AU2016342578A1 (cg-RX-API-DMAC10.html)
CA (1) CA3002622A1 (cg-RX-API-DMAC10.html)
HK (1) HK1251481A1 (cg-RX-API-DMAC10.html)
IL (3) IL257723B2 (cg-RX-API-DMAC10.html)
RU (2) RU2728710C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017068472A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356279B (es) 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RU2728710C2 (ru) * 2015-10-19 2020-07-30 Новартис Аг Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
WO2018236728A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2020221737A1 (en) * 2019-04-29 2020-11-05 UCB Biopharma SRL Medical image analysis system and method for identification of lesions
EP4031570A1 (en) * 2019-09-20 2022-07-27 Novartis AG Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CA3196991A1 (en) * 2020-11-05 2022-05-12 Florence Wing Ling Tsui Methods for systematically assessing local inflammation and active repair
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059598A2 (en) * 2010-11-05 2012-05-10 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
WO2013158821A2 (en) * 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
RU2728710C2 (ru) 2015-10-19 2020-07-30 Новартис Аг Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059598A2 (en) * 2010-11-05 2012-05-10 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
WO2013158821A2 (en) * 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ODDUBNYY D. et al, Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update, Expert Opin. Biol. Ther., 2013, vol. 13, no. 11, pages 1599 - 1611, DOI:http://dx.doi.org/10.1517/14712598.2013.839653. *
PODDUBNYY D. et al, Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update, Expert Opin. Biol. Ther., 2013, vol. 13, no. 11, pages 1599 - 1611, DOI:http://dx.doi.org/10.1517/14712598.2013.839653. ШОСТАК Н.А. и др., Боль в спине воспалительного генеза: серонегативные спондилоартропатии - основные подходы к диагностике и терапии, Трудный пациент, 2011, N 1, Т. 9, С. 48-50. *
ШОСТАК Н.А. и др., Боль в спине воспалительного генеза: серонегативные спондилоартропатии - основные подходы к диагностике и терапии, Трудный пациент, 2011, N 1, Т. 9, С. 48-50. *

Also Published As

Publication number Publication date
AU2021240290A1 (en) 2021-11-11
US20190330328A1 (en) 2019-10-31
RU2020124276A3 (cg-RX-API-DMAC10.html) 2022-01-18
WO2017068472A1 (en) 2017-04-27
RU2018118177A3 (cg-RX-API-DMAC10.html) 2020-02-17
IL257723B2 (en) 2023-04-01
JP7389077B2 (ja) 2023-11-29
JP2023134701A (ja) 2023-09-27
JP6858766B2 (ja) 2021-04-14
HK1251481A1 (zh) 2019-02-01
AU2016342578A1 (en) 2018-03-29
KR20180064415A (ko) 2018-06-14
EP3365011A1 (en) 2018-08-29
RU2018118177A (ru) 2019-11-21
IL257723A (en) 2018-04-30
CN108367074A (zh) 2018-08-03
JP2018537418A (ja) 2018-12-20
AU2019240551A1 (en) 2019-10-17
JP2021100956A (ja) 2021-07-08
RU2020124276A (ru) 2021-08-03
IL328279A (en) 2026-07-01
IL257723B (en) 2022-12-01
JP2026010006A (ja) 2026-01-21
IL297775A (en) 2022-12-01
CA3002622A1 (en) 2017-04-27
AU2024278118A1 (en) 2025-01-02
US20250066466A1 (en) 2025-02-27
IL297775B1 (en) 2026-06-01

Similar Documents

Publication Publication Date Title
JP7389077B2 (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
US20220313818A1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritic patients
US12497449B2 (en) Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
WO2021035129A1 (en) Use of brazikumab to treat crohn's disease
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients